F8 and hepatitis C virus infection: The introduction of heat-treated concentrates in 1985 diminished the risk of HIV and hepatitis C infections[3], while the first recombinant clotting factor products (in 1992 for FVIII and 1997 for FIX) resulted in the eradication of haematogenous HIV and hepatitis C infections.